PhaseBio Pharmaceuticals Receivables

Receivables of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Receivables growth rates and interactive chart. Accounts receivable (AR) is the balance of money due to a firm for goods or services delivered or used but not yet paid for by customers. Accounts receivables are listed on the balance sheet as a current asset. AR is any amount of money owed by customers for purchases made on credit. When a company makes a sale, it records revenues and a corresponding balance in accounts receivable. When an invoice is paid, the accounts payable account is reduced and cash is received. Receivables should grow in-line with revenue over time, if they are growing much faster, a company might be booking revenue too aggressively.


Highlights and Quick Summary

  • Receivables for the quarter ending June 29, 2021 was $18.4 Million (a 1953.57% increase compared to previous quarter)
  • Year-over-year quarterly Receivables increased by 3056.09%
  • Annual Receivables for 2019 was $1.23 Million (a 429.18% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Receivables of PhaseBio Pharmaceuticals

Most recent Receivablesof PHAS including historical data for past 10 years.

Interactive Chart of Receivables of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Receivables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $18.4
2020 $0.9
2019 $1.23 $0.58 $1.18 $0.67 $1.23
2018 $0.23 $0.41 $0.23

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.